Redeye: Vitrolife Update - Modest stable growth with great margins
Vitrolife delivered a consecutive positive organic growth recovery with 6% organic growth in constant currencies (CER). The last three quarters are near market growth. The extra 4-5% growth needed to reach its target of >10% will take longer, considering that some 3% of Vitrolife’s business will fade out to comply with sanctions and international policies during 2025.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/